Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last?Zacks Investment Research • 10/22/25
Arcturus Therapeutics (ARCT) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 10/15/25
Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?Zacks Investment Research • 09/19/25
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call TranscriptSeeking Alpha • 08/12/25
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/11/25
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline ProgressBusiness Wire • 08/11/25
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025Business Wire • 07/24/25
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency ProgramBusiness Wire • 06/30/25
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) DeficiencyBusiness Wire • 06/23/25
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a BetZacks Investment Research • 06/03/25
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to TradeZacks Investment Research • 05/15/25
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/12/25
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline ProgressBusiness Wire • 05/12/25
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to DeclineZacks Investment Research • 05/05/25
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025Business Wire • 04/22/25
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine CandidateZacks Investment Research • 04/11/25
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1Business Wire • 04/10/25
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline ProgressBusiness Wire • 03/06/25
Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025Business Wire • 03/05/25
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025Business Wire • 02/24/25
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccinePRNewsWire • 02/14/25